Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer.

Gregory J Riely,Egbert F Smit,Myung-Ju Ahn,Enriqueta Felip,Suresh S Ramalingam,Anne Tsao,Melissa Johnson,Francesco Gelsomino, Raymond Esper,Ernest Nadal,Michael Offin,Mariano Provencio, Jeffrey Clarke, Maen Hussain,Gregory A Otterson,Ibiayi Dagogo-Jack,Jonathan W Goldman,Daniel Morgensztern,Ann Alcasid,Tiziana Usari, Paul Wissel,Keith Wilner,Nuzhat Pathan, Svitlana Tonkovyd,Bruce E Johnson

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 1|浏览32

暂无评分

摘要

For patients with treatment-naïve and previously treated -mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要